MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
MetaVia (Nasdaq: MTVA) has announced a strategic research collaboration with Syntekabio to expand therapeutic applications of DA-1241, their oral GPR119 agonist. The partnership will utilize Syntekabio's DeepMatcher® AI platform to screen DA-1241 against over 1,700 protein targets for new indications.
The collaboration follows positive Phase 2a results from a 16-week study involving 109 subjects, which demonstrated favorable safety and tolerability profiles, along with hepatoprotective and glucose-regulating effects in MASH patients. Initial insights from this AI-driven collaboration are expected later in 2025.
MetaVia (Nasdaq: MTVA) ha annunciato una collaborazione strategica di ricerca con Syntekabio per ampliare le applicazioni terapeutiche di DA-1241, il loro agonista orale del GPR119. La partnership utilizzerà la piattaforma AI DeepMatcher® di Syntekabio per analizzare DA-1241 su oltre 1.700 bersagli proteici alla ricerca di nuove indicazioni.
La collaborazione segue i risultati positivi della Fase 2a di uno studio di 16 settimane su 109 soggetti, che hanno mostrato un profilo di sicurezza e tollerabilità favorevole, insieme a effetti epatoprotettivi e regolatori del glucosio nei pazienti con MASH. I primi risultati di questa collaborazione basata sull'IA sono attesi per la fine del 2025.
MetaVia (Nasdaq: MTVA) ha anunciado una colaboración estratégica de investigación con Syntekabio para ampliar las aplicaciones terapéuticas de DA-1241, su agonista oral del GPR119. La asociación utilizará la plataforma de IA DeepMatcher® de Syntekabio para evaluar DA-1241 contra más de 1,700 objetivos proteicos en busca de nuevas indicaciones.
La colaboración sigue a los resultados positivos de la Fase 2a de un estudio de 16 semanas con 109 sujetos, que demostraron un perfil favorable de seguridad y tolerabilidad, junto con efectos hepatoprotectores y reguladores de la glucosa en pacientes con MASH. Se esperan las primeras conclusiones de esta colaboración impulsada por IA a finales de 2025.
MetaVia (나스닥: MTVA)는 경구용 GPR119 작용제인 DA-1241의 치료 적용 범위를 확장하기 위해 Syntekabio와 전략적 연구 협력을 발표했습니다. 이번 파트너십은 Syntekabio의 DeepMatcher® AI 플랫폼을 활용하여 DA-1241을 1,700개 이상의 단백질 타깃에 대해 스크리닝하여 새로운 적응증을 탐색할 예정입니다.
이번 협력은 109명의 대상자를 대상으로 16주간 진행된 2a상 긍정적 결과를 바탕으로 하며, 안전성과 내약성이 우수하고 MASH 환자에서 간 보호 및 혈당 조절 효과를 확인했습니다. AI 기반 협력의 초기 결과는 2025년 후반에 발표될 예정입니다.
MetaVia (Nasdaq : MTVA) a annoncé une collaboration stratégique de recherche avec Syntekabio pour élargir les applications thérapeutiques de DA-1241, leur agoniste oral du GPR119. Le partenariat utilisera la plateforme IA DeepMatcher® de Syntekabio pour analyser DA-1241 sur plus de 1 700 cibles protéiques afin de découvrir de nouvelles indications.
Cette collaboration fait suite aux résultats positifs de la phase 2a d'une étude de 16 semaines portant sur 109 sujets, qui ont montré un profil de sécurité et de tolérance favorable, ainsi que des effets hépatoprotecteurs et régulateurs de la glycémie chez des patients atteints de MASH. Les premiers résultats issus de cette collaboration pilotée par l’IA sont attendus fin 2025.
MetaVia (Nasdaq: MTVA) hat eine strategische Forschungskooperation mit Syntekabio angekündigt, um die therapeutischen Anwendungen von DA-1241, ihrem oralen GPR119-Agonisten, zu erweitern. Die Partnerschaft wird die DeepMatcher® KI-Plattform von Syntekabio nutzen, um DA-1241 gegen über 1.700 Proteinziele auf neue Indikationen zu untersuchen.
Die Zusammenarbeit folgt auf positive Ergebnisse der Phase 2a einer 16-wöchigen Studie mit 109 Probanden, die günstige Sicherheits- und Verträglichkeitsprofile sowie hepato-protektive und glucoseregulierende Effekte bei MASH-Patienten zeigte. Erste Erkenntnisse aus dieser KI-basierten Kooperation werden für Ende 2025 erwartet.
- Positive Phase 2a results showing favorable safety and tolerability profile
- Demonstrated hepatoprotective and glucose-regulating effects in MASH patients
- Access to AI platform screening against 1,700+ protein targets
- Potential expansion into additional therapeutic indications
- None.
Insights
MetaVia's AI partnership with Syntekabio expands potential applications for their promising GPR119 agonist beyond MASH after positive Phase 2a results.
MetaVia's new collaboration with Syntekabio represents a strategic expansion of their lead candidate DA-1241's potential market reach. The partnership comes at an opportune moment, following positive Phase 2a results in 109 MASH patients that demonstrated both favorable safety and efficacy signals—specifically hepatoprotective and glucose-regulating effects.
What makes this collaboration particularly significant is the application of Syntekabio's DeepMatcher® AI platform, which will screen DA-1241 against more than 1,700 validated protein targets. This approach substantially increases the chances of identifying additional indications while simultaneously reducing development risk by ensuring target specificity and minimizing off-target effects.
The GPR119 receptor pathway represents an intriguing therapeutic target with broad metabolic implications. GPR119 agonists like DA-1241 can enhance glucose-dependent insulin secretion and improve glycemic control through multiple mechanisms. While initially positioned for MASH, the receptor's expression profile suggests potential applications across multiple metabolic disorders.
For MetaVia, this AI-driven approach to indication expansion represents a capital-efficient strategy to potentially increase their lead asset's commercial value without initiating costly new discovery programs. Initial insights expected later this year could accelerate development timelines for any newly identified indications, potentially creating multiple parallel value streams from a single molecular entity.
Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of
MetaVia's Oral GPR119 Agonist
This collaboration follows positive results from MetaVia's 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients.
"The strong safety and tolerability profile shown in our Phase 2a data gives us confidence in DA-1241's broader therapeutic potential," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Building on this clinical foundation, we are collaborating with Syntekabio to strategically expand the potential value of DA-1241. Specifically, we will leverage their proprietary DeepMatcher® compound-protein interaction (CPI) AI prediction platform to conduct large-scale virtual screening against more than 1,700 validated protein targets to uncover new, high-potential indications while ensuring specificity and minimizing the risk of off-target effects. This data-driven approach will allow us to accelerate discovery and maximize the value of DA-1241. We believe this unique oral, well-tolerated candidate has the potential to address a range of unmet needs, and we look forward to initial insights from the collaboration later this year."
About DA-1241
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio's disease-agnostic platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241-302520330.html
SOURCE MetaVia Inc.
FAQ
What are the Phase 2a results for MetaVia's DA-1241 drug candidate?
How will Syntekabio's AI platform benefit MetaVia's DA-1241 development?
What is the current development stage of MetaVia's DA-1241?
When will MetaVia (MTVA) receive initial results from the Syntekabio collaboration?
What is the mechanism of action for MetaVia's DA-1241?
